All In Biotech

Drug Trial Radar · NCT05947851

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 735 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

735

Planned (sponsor's estimate)

Start

Aug 8, 2023

Primary completion

Jun 1, 2032

Study completion Jul 1, 2035

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Chronic Lymphocytic
  • Small-Cell Lymphoma
  • Lymphoma, Small Lymphocytic
  • CLL
  • SLL

Interventions

  • NemtabrutinibDrug

    5, 20, and 45 tablets

  • VenetoclaxDrug

    10, 50, and 100 mg tablets

  • RituximabBiological

    100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 12 Weeks
  2. Part 1: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 28 months
  3. Part 1: Number of Participants Discontinuing Study Treatment Due to AEsTime frame: Up to approximately 25 months
  4. Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 71 months

Locations

107 sites in 23 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group ( Site 5405)

    Springdale, Arkansas · Recruiting

  • MemorialCare Health System - Long Beach Medical Center ( Site 5421)

    Long Beach, California · Recruiting

  • Clermont Oncology Center ( Site 5430)

    Clermont, Florida · Recruiting

  • Memorial Hospital West ( Site 5410)

    Pembroke Pines, Florida · Recruiting

  • Fort Wayne Medical Oncology and Hematology ( Site 5444)

    Fort Wayne, Indiana · Recruiting

  • Center for Cancer and Blood Disorders ( Site 5439)

    Bethesda, Maryland · Recruiting

  • Avera Cancer Institute - Marshall ( Site 5462)

    Marshall, Minnesota · Recruiting

  • Hattiesburg Clinic Hematology/Oncology ( Site 5416)

    Hattiesburg, Mississippi · Recruiting

  • MidAmerica Cancer Care, LLC ( Site 5426)

    Kansas City, Missouri · Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 5433)

    Billings, Montana · Recruiting

  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 5434)

    Reno, Nevada · Recruiting

  • Atlantic Health System Morristown Medical Center ( Site 5445)

    Morristown, New Jersey · Recruiting

  • New York Oncology Hematology, P.C. ( Site 5453)

    Albany, New York · Recruiting

  • Oregon Health and Science University ( Site 5425)

    Portland, Oregon · Recruiting

  • Avera Cancer Institute - Aberdeen ( Site 5458)

    Aberdeen, South Dakota · Recruiting

  • Avera Cancer Institute - Mitchell ( Site 5461)

    Mitchell, South Dakota · Recruiting

  • Avera Cancer Institute - Pierre ( Site 5460)

    Pierre, South Dakota · Recruiting

  • Avera Cancer Institute- Research ( Site 5437)

    Sioux Falls, South Dakota · Recruiting

  • Avera Cancer Institute - Yankton ( Site 5459)

    Yankton, South Dakota · Recruiting

  • PatientCare Clinical Research LLC ( Site 5435)

    Sugar Land, Texas · Recruiting

  • University of Virginia Cancer Center ( Site 5402)

    Charlottesville, Virginia · Recruiting

  • Vista Oncology ( Site 5449)

    Olympia, Washington · Recruiting

  • Medical Oncology Associates, PS ( Site 5406)

    Spokane, Washington · Recruiting

  • West Virginia University ( Site 5447)

    Morgantown, West Virginia · Recruiting

  • University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)

    Madison, Wisconsin · Completed

  • Centro Medico Fleischer ( Site 1006)

    Buenos Aires, Argentina · Recruiting

  • Hospital Aleman-oncohematologic diseases ( Site 1001)

    Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 1005)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Sanatorio Parque ( Site 1003)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Royal Adelaide Hospital ( Site 1104)

    Adelaide, South Australia, Australia · Recruiting

  • Box Hill Hospital ( Site 1106)

    Box Hill, Victoria, Australia · Recruiting

  • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)

    Melbourne, Victoria, Australia · Recruiting

  • ZAS Cadix ( Site 1203)

    Antwerp, Belgium · Recruiting

  • UZ Leuven-Hematology ( Site 1200)

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)

    São Paulo, Brazil · Active not recruiting

  • Hospital Paulistano-Americas Oncologia ( Site 1302)

    São Paulo, Brazil · Recruiting

  • Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304)

    Jaú, São Paulo, Brazil · Recruiting

  • The Moncton Hospital ( Site 1414)

    Moncton, New Brunswick, Canada · Recruiting

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.